Please use this identifier to cite or link to this item: http://hdl.handle.net/11054/2963
Full metadata record
DC FieldValueLanguage
dc.contributorLivori, Adamen_US
dc.contributorZiser, K.en_US
dc.contributorAppay, M.en_US
dc.contributorPotts, C.en_US
dc.contributorLai, B.en_US
dc.date.accessioned2025-01-15T06:39:45Z-
dc.date.available2025-01-15T06:39:45Z-
dc.date.issued2024-
dc.identifier.govdoc02833en_US
dc.identifier.urihttp://hdl.handle.net/11054/2963-
dc.description.abstractBackground: Non-vitamin K antagonist oral anticoagulants (NOAC) are recommended as first-line anticoagulation therapy for stroke prevention in patients with non-valvular atrial fibrillation (NVAF). However, real-world data on pharmacists’ practice patterns in under-represented populations, such as patients with advanced age, obesity and end-stage kidney disease (ESKD), are lacking. Aim: To explore pharmacists’ perceptions and trends in using NOACs among patients with NVAF and advanced age, obesity or ESKD. Method: In this cross-sectional, self-administered survey, Australian pharmacists who were members of several specialty practice streams of the Society of Hospital Pharmacists of Australia were surveyed. Results: There were 33/145 (23%) of practice group members who responded. Apixaban (74%, 17/23) was indicated to be the preferred anticoagulant for use in advanced age. 91% (21/23) of pharmacists indicated that NOAC doses were reduced in accordance with product information (PI) in their daily practice, and 22% (5/23) indicated they would recommend reducing a NOAC dose outside of PI recommendations. In obesity, most respondents indicated that warfarin was the anticoagulant of choice (52%, 12/23). In renal disease, 9% (2/21) of pharmacists would recommend a dose reduction outside of the PI, indicating they were willing to use and initiate apixaban down to a CrCl of 10 mL/min for NVAF but not other NOACs. In haemodialysis, 57% (12/21) of pharmacists preferred to use warfarin. Conclusion: This survey indicates that diversity exists in the use of NOACs among patients with NVAF and advanced age, obesity or ESKD in Australia and that disparities from available literature are occurring in daily practice.en_US
dc.description.provenanceSubmitted by Gemma Siemensma (gemmas@bhs.org.au) on 2024-11-04T00:18:53Z No. of bitstreams: 1 LIVORI SHPA CSANZ posters.pdf: 990835 bytes, checksum: 184e2e364799ee497d7807d82b90199b (MD5)en
dc.description.provenanceApproved for entry into archive by Gemma Siemensma (gemmas@bhs.org.au) on 2025-01-15T06:39:45Z (GMT) No. of bitstreams: 1 LIVORI SHPA CSANZ posters.pdf: 990835 bytes, checksum: 184e2e364799ee497d7807d82b90199b (MD5)en
dc.description.provenanceMade available in DSpace on 2025-01-15T06:39:45Z (GMT). No. of bitstreams: 1 LIVORI SHPA CSANZ posters.pdf: 990835 bytes, checksum: 184e2e364799ee497d7807d82b90199b (MD5) Previous issue date: 2024en
dc.titleNon-vitamin K antagonist oral anticoagulant use in underrepresented populations in atrial fibrillation: A survey of Australian pharmacist practice (Poster).en_US
dc.typeConferenceen_US
dc.type.specifiedPosteren_US
dc.bibliographicCitation.conferencedateAugust 1-4en_US
dc.bibliographicCitation.conferencename72nd Annual Scientific Meeting of the Cardiac Society of Australia and New Zealanden_US
dc.bibliographicCitation.conferenceplacePerth, Australiaen_US
dc.subject.healththesaurusCARDIOLOGYen_US
dc.subject.healththesaurusMEDICATION MANAGEMENTen_US
Appears in Collections:Research Output

Files in This Item:
File Description SizeFormat  
LIVORI SHPA CSANZ posters.pdf967.61 kBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.